ArticleFrontiers in pharmacology2021
Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Hongfu Cai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
33 papers cite it
this paperpooled itcites it